TY - JOUR AU - Carnio, S. AU - Novello, S. AU - Mele, T. AU - Levra, M. G. AU - Scagliotti, G. V. PY - 2014 DA - 2014// TI - Extending survival of stage IV non-small cell lung cancer JO - Semin Oncol. VL - 41 UR - https://doi.org/10.1053/j.seminoncol.2013.12.013 DO - 10.1053/j.seminoncol.2013.12.013 ID - Carnio2014 ER - TY - JOUR AU - Siegel, R. AU - Naishadham, D. AU - Jemal, A. PY - 2013 DA - 2013// TI - Cancer statistics, 2013 JO - CA Cancer J Clin. VL - 63 UR - https://doi.org/10.3322/caac.21166 DO - 10.3322/caac.21166 ID - Siegel2013 ER - TY - JOUR AU - Abourbeh, G. AU - Shir, A. AU - Mishani, E. AU - Ogris, M. AU - Rodl, W. AU - Wagner, E. PY - 2012 DA - 2012// TI - PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors JO - IUBMB Life. VL - 64 UR - https://doi.org/10.1002/iub.1002 DO - 10.1002/iub.1002 ID - Abourbeh2012 ER - TY - JOUR AU - Chen, P. AU - Cameron, R. AU - Wang, J. AU - Vallis, K. A. AU - Reilly, R. M. PY - 2003 DA - 2003// TI - Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts JO - J Nucl Med. VL - 44 ID - Chen2003 ER - TY - JOUR AU - Mamot, C. AU - Drummond, D. C. AU - Greiser, U. AU - Hong, K. AU - Kirpotin, D. B. AU - Marks, J. D. PY - 2003 DA - 2003// TI - Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells JO - Cancer Res. VL - 63 ID - Mamot2003 ER - TY - JOUR AU - Ratti, M. AU - Tomasello, G. PY - 2014 DA - 2014// TI - Emerging combination therapies to overcome resistance in EGFR-driven tumors JO - Anticancer Drugs. VL - 25 UR - https://doi.org/10.1097/CAD.0000000000000035 DO - 10.1097/CAD.0000000000000035 ID - Ratti2014 ER - TY - JOUR AU - Lynch, T. J. AU - Bell, D. W. AU - Sordella, R. AU - Gurubhagavatula, S. AU - Okimoto, R. A. AU - Brannigan, B. W. PY - 2004 DA - 2004// TI - Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib JO - N Engl J Med. VL - 350 UR - https://doi.org/10.1056/NEJMoa040938 DO - 10.1056/NEJMoa040938 ID - Lynch2004 ER - TY - JOUR AU - Paez, J. G. AU - Janne, P. A. AU - Lee, J. C. AU - Tracy, S. AU - Greulich, H. AU - Gabriel, S. PY - 2004 DA - 2004// TI - EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy JO - Science. VL - 304 UR - https://doi.org/10.1126/science.1099314 DO - 10.1126/science.1099314 ID - Paez2004 ER - TY - JOUR AU - Sordella, R. AU - Bell, D. W. AU - Haber, D. A. AU - Settleman, J. PY - 2004 DA - 2004// TI - Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways JO - Science. VL - 305 UR - https://doi.org/10.1126/science.1101637 DO - 10.1126/science.1101637 ID - Sordella2004 ER - TY - JOUR AU - Dillon, B. AU - Naidoo, B. AU - Knight, H. AU - Clark, P. PY - 2012 DA - 2012// TI - NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer JO - Lancet Oncol. VL - 13 UR - https://doi.org/10.1016/S1470-2045(12)70296-6 DO - 10.1016/S1470-2045(12)70296-6 ID - Dillon2012 ER - TY - JOUR AU - Rosell, R. AU - Carcereny, E. AU - Gervais, R. AU - Vergnenegre, A. AU - Massuti, B. AU - Felip, E. PY - 2012 DA - 2012// TI - Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial JO - Lancet Oncol. VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70393-X DO - 10.1016/S1470-2045(11)70393-X ID - Rosell2012 ER - TY - JOUR AU - Riely, G. J. AU - Kris, M. G. AU - Zhao, B. AU - Akhurst, T. AU - Milton, D. T. AU - Moore, E. PY - 2007 DA - 2007// TI - Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus JO - Clin Cancer Res. VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-07-0560 DO - 10.1158/1078-0432.CCR-07-0560 ID - Riely2007 ER - TY - JOUR AU - Yu, H. A. AU - Arcila, M. E. AU - Rekhtman, N. AU - Sima, C. S. AU - Zakowski, M. F. AU - Pao, W. PY - 2013 DA - 2013// TI - Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers JO - Clin Cancer Res. VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-2246 DO - 10.1158/1078-0432.CCR-12-2246 ID - Yu2013 ER - TY - JOUR AU - Zhao, J. AU - Wang, X. AU - Xue, L. AU - Xu, N. AU - Ye, X. AU - Zeng, H. PY - 2014 DA - 2014// TI - The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer JO - J Cancer Res Clin Oncol. VL - 140 UR - https://doi.org/10.1007/s00432-014-1618-2 DO - 10.1007/s00432-014-1618-2 ID - Zhao2014 ER - TY - JOUR AU - Peled, N. AU - Barash, O. AU - Tisch, U. AU - Ionescu, R. AU - Broza, Y. Y. AU - Ilouze, M. PY - 2013 DA - 2013// TI - Volatile fingerprints of cancer specific genetic mutations JO - Nanomedicine. VL - 9 UR - https://doi.org/10.1016/j.nano.2013.01.008 DO - 10.1016/j.nano.2013.01.008 ID - Peled2013 ER - TY - JOUR AU - Yeh, H. H. AU - Ogawa, K. AU - Balatoni, J. AU - Mukhapadhyay, U. AU - Pal, A. AU - Gonzalez-Lepera, C. PY - 2011 DA - 2011// TI - Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT JO - Proc Natl Acad Sci U S A. VL - 108 UR - https://doi.org/10.1073/pnas.1010744108 DO - 10.1073/pnas.1010744108 ID - Yeh2011 ER - TY - JOUR AU - Abourbeh, G. AU - Dissoki, S. AU - Jacobson, O. AU - Litchi, A. AU - Ben Daniel, R. AU - Laki, D. PY - 2007 DA - 2007// TI - Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors JO - Nucl Med Biol. VL - 34 UR - https://doi.org/10.1016/j.nucmedbio.2006.10.012 DO - 10.1016/j.nucmedbio.2006.10.012 ID - Abourbeh2007 ER - TY - JOUR AU - Bahce, I. AU - Smit, E. F. AU - Lubberink, M. AU - Veldt, A. A. AU - Yaqub, M. AU - Windhorst, A. D. PY - 2012 DA - 2012// TI - Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status JO - Clin Cancer Res. VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-0289 DO - 10.1158/1078-0432.CCR-12-0289 ID - Bahce2012 ER - TY - JOUR AU - Memon, A. A. AU - Jakobsen, S. AU - Dagnaes-Hansen, F. AU - Sorensen, B. S. AU - Keiding, S. AU - Nexo, E. PY - 2009 DA - 2009// TI - Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts JO - Cancer Res. VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-3118 DO - 10.1158/0008-5472.CAN-08-3118 ID - Memon2009 ER - TY - JOUR AU - Memon, A. A. AU - Weber, B. AU - Winterdahl, M. AU - Jakobsen, S. AU - Meldgaard, P. AU - Madsen, H. H. PY - 2011 DA - 2011// TI - PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer JO - Br J Cancer. VL - 105 UR - https://doi.org/10.1038/bjc.2011.493 DO - 10.1038/bjc.2011.493 ID - Memon2011 ER - TY - JOUR AU - Meng, X. AU - Loo, B. W. AU - Ma, L. AU - Murphy, J. D. AU - Sun, X. AU - Yu, J. PY - 2011 DA - 2011// TI - Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study JO - J Nucl Med. VL - 52 UR - https://doi.org/10.2967/jnumed.111.092874 DO - 10.2967/jnumed.111.092874 ID - Meng2011 ER - TY - JOUR AU - Mishani, E. AU - Hagooly, A. PY - 2009 DA - 2009// TI - Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer JO - J Nucl Med. VL - 50 UR - https://doi.org/10.2967/jnumed.109.062117 DO - 10.2967/jnumed.109.062117 ID - Mishani2009 ER - TY - JOUR AU - Pal, A. AU - Glekas, A. AU - Doubrovin, M. AU - Balatoni, J. AU - Namavari, M. AU - Beresten, T. PY - 2006 DA - 2006// TI - Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography JO - Mol Imaging Biol. VL - 8 UR - https://doi.org/10.1007/s11307-006-0049-0 DO - 10.1007/s11307-006-0049-0 ID - Pal2006 ER - TY - JOUR AU - Petrulli, J. R. AU - Sullivan, J. M. AU - Zheng, M. Q. AU - Bennett, D. C. AU - Charest, J. AU - Huang, Y. PY - 2013 DA - 2013// TI - Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain JO - Neoplasia. VL - 15 ID - Petrulli2013 ER - TY - JOUR AU - Slobbe, P. AU - Poot, A. J. AU - Windhorst, A. D. AU - Dongen, G. A. PY - 2012 DA - 2012// TI - PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET JO - Drug Discov Today. VL - 17 UR - https://doi.org/10.1016/j.drudis.2012.06.016 DO - 10.1016/j.drudis.2012.06.016 ID - Slobbe2012 ER - TY - JOUR AU - Su, H. AU - Seimbille, Y. AU - Ferl, G. Z. AU - Bodenstein, C. AU - Fueger, B. AU - Kim, K. J. PY - 2008 DA - 2008// TI - Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors JO - Eur J Nucl Med Mol Imaging. VL - 35 UR - https://doi.org/10.1007/s00259-007-0636-6 DO - 10.1007/s00259-007-0636-6 ID - Su2008 ER - TY - JOUR AU - Dongen, G. A. AU - Poot, A. J. AU - Vugts, D. J. PY - 2012 DA - 2012// TI - PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET JO - Tumour Biol. VL - 33 UR - https://doi.org/10.1007/s13277-012-0316-4 DO - 10.1007/s13277-012-0316-4 ID - Dongen2012 ER - TY - JOUR AU - Weber, B. AU - Winterdahl, M. AU - Memon, A. AU - Sorensen, B. S. AU - Keiding, S. AU - Sorensen, L. PY - 2011 DA - 2011// TI - Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor JO - J Thorac Oncol. VL - 6 UR - https://doi.org/10.1097/JTO.0b013e318219ab87 DO - 10.1097/JTO.0b013e318219ab87 ID - Weber2011 ER - TY - JOUR AU - Zhang, M. R. AU - Kumata, K. AU - Hatori, A. AU - Takai, N. AU - Toyohara, J. AU - Yamasaki, T. PY - 2010 DA - 2010// TI - [11C]Gefitinib ([11c]Iressa): radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma JO - Mol Imaging Biol VL - 12 UR - https://doi.org/10.1007/s11307-009-0265-5 DO - 10.1007/s11307-009-0265-5 ID - Zhang2010 ER - TY - JOUR AU - Dent, M. F. AU - Hubbold, L. AU - Radford, H. AU - Wilson, A. P. PY - 1995 DA - 1995// TI - The methylene blue colorimetric microassay for determining cell line response to growth factors JO - Cytotechnology. VL - 17 UR - https://doi.org/10.1007/BF00749218 DO - 10.1007/BF00749218 ID - Dent1995 ER - TY - JOUR AU - Abourbeh, G. AU - Theze, B. AU - Maroy, R. AU - Dubois, A. AU - Brulon, V. AU - Fontyn, Y. PY - 2012 DA - 2012// TI - Imaging microglial/macrophage activation in spinal cords of experimental autoimmune encephalomyelitis rats by positron emission tomography using the mitochondrial 18 kDa translocator protein radioligand [(1)(8)F]DPA-714 JO - J Neurosci. VL - 32 UR - https://doi.org/10.1523/JNEUROSCI.2900-11.2012 DO - 10.1523/JNEUROSCI.2900-11.2012 ID - Abourbeh2012 ER - TY - JOUR AU - Han, S. W. AU - Kim, T. Y. AU - Hwang, P. G. AU - Jeong, S. AU - Kim, J. AU - Choi, I. S. PY - 2005 DA - 2005// TI - Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib JO - J Clin Oncol. VL - 23 UR - https://doi.org/10.1200/JCO.2005.01.388 DO - 10.1200/JCO.2005.01.388 ID - Han2005 ER - TY - JOUR AU - Parra, H. S. AU - Cavina, R. AU - Latteri, F. AU - Zucali, P. A. AU - Campagnoli, E. AU - Morenghi, E. PY - 2004 DA - 2004// TI - Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer JO - Br J Cancer. VL - 91 ID - Parra2004 ER - TY - JOUR AU - Conti, P. S. AU - White, C. AU - Pieslor, P. AU - Molina, A. AU - Aussie, J. AU - Foster, P. PY - 2005 DA - 2005// TI - The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: results from a Zevalin Imaging Registry JO - J Nucl Med. VL - 46 ID - Conti2005 ER - TY - JOUR AU - Druker, B. J. AU - Guilhot, F. AU - O'Brien, S. G. AU - Gathmann, I. AU - Kantarjian, H. AU - Gattermann, N. PY - 2006 DA - 2006// TI - Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia JO - N Engl J Med. VL - 355 UR - https://doi.org/10.1056/NEJMoa062867 DO - 10.1056/NEJMoa062867 ID - Druker2006 ER - TY - JOUR AU - Teunissen, J. J. AU - Kwekkeboom, D. J. AU - Valkema, R. AU - Krenning, E. P. PY - 2011 DA - 2011// TI - Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours JO - Endocr Relat Cancer. VL - 18 UR - https://doi.org/10.1530/ERC-10-0282 DO - 10.1530/ERC-10-0282 ID - Teunissen2011 ER - TY - JOUR AU - Velikyan, I. AU - Sundin, A. AU - Sorensen, J. AU - Lubberink, M. AU - Sandstrom, M. AU - Garske-Roman, U. PY - 2014 DA - 2014// TI - Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification JO - J Nucl Med. VL - 55 UR - https://doi.org/10.2967/jnumed.113.126177 DO - 10.2967/jnumed.113.126177 ID - Velikyan2014 ER - TY - JOUR AU - Cadranel, J. AU - Ruppert, A. M. AU - Beau-Faller, M. AU - Wislez, M. PY - 2013 DA - 2013// TI - Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma JO - Crit Rev Oncol Hematol. VL - 88 UR - https://doi.org/10.1016/j.critrevonc.2013.06.009 DO - 10.1016/j.critrevonc.2013.06.009 ID - Cadranel2013 ER - TY - JOUR AU - Sharma, S. V. AU - Bell, D. W. AU - Settleman, J. AU - Haber, D. A. PY - 2007 DA - 2007// TI - Epidermal growth factor receptor mutations in lung cancer JO - Nat Rev Cancer. VL - 7 UR - https://doi.org/10.1038/nrc2088 DO - 10.1038/nrc2088 ID - Sharma2007 ER - TY - JOUR AU - Eckelman, W. C. PY - 1994 DA - 1994// TI - The application of receptor theory to receptor-binding and enzyme-binding oncologic radiopharmaceuticals JO - Nucl Med Biol. VL - 21 UR - https://doi.org/10.1016/0969-8051(94)90047-7 DO - 10.1016/0969-8051(94)90047-7 ID - Eckelman1994 ER - TY - JOUR AU - Carey, K. D. AU - Garton, A. J. AU - Romero, M. S. AU - Kahler, J. AU - Thomson, S. AU - Ross, S. PY - 2006 DA - 2006// TI - Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib JO - Cancer Res. VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-06-0453 DO - 10.1158/0008-5472.CAN-06-0453 ID - Carey2006 ER - TY - JOUR AU - Frings, V. AU - Yaqub, M. AU - Hoyng, L. L. AU - Golla, S. S. AU - Windhorst, A. D. AU - Schuit, R. C. PY - 2014 DA - 2014// TI - Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment JO - J Nucl Med. VL - 55 UR - https://doi.org/10.2967/jnumed.114.140913 DO - 10.2967/jnumed.114.140913 ID - Frings2014 ER - TY - JOUR AU - Iommelli, F. AU - Rosa, V. AU - Gargiulo, S. AU - Panico, M. AU - Monti, M. AU - Greco, A. PY - 2014 DA - 2014// TI - Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3′-deoxy-3′-[18F]-fluorothymidine positron emission tomography JO - Clin Cancer Res. VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-14-0264 DO - 10.1158/1078-0432.CCR-14-0264 ID - Iommelli2014 ER - TY - JOUR AU - Zannetti, A. AU - Iommelli, F. AU - Speranza, A. AU - Salvatore, M. AU - Vecchio, S. PY - 2012 DA - 2012// TI - 3′-Deoxy-3′-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer JO - J Nucl Med. VL - 53 UR - https://doi.org/10.2967/jnumed.111.096503 DO - 10.2967/jnumed.111.096503 ID - Zannetti2012 ER - TY - JOUR AU - Sohn, H. J. AU - Yang, Y. J. AU - Ryu, J. S. AU - Oh, S. J. AU - Im, K. C. AU - Moon, D. H. PY - 2008 DA - 2008// TI - [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-08-0312 DO - 10.1158/1078-0432.CCR-08-0312 ID - Sohn2008 ER -